Merck Stock Surges 1.87% with $9.51 Billion Trading Volume Ranking 71st as Phase 3 Dengue Vaccine Trial Begins

On June 12, 2025, Merck & Co. (MRK) saw a trading volume of $9.51 billion, ranking 71st in the day's stock market activity. The company's stock price increased by 1.87%.

Merck has initiated a Phase 3 clinical trial, known as MOBILIZE-1 or V181-005, to evaluate the safety, immunogenicity, and efficacy of its dengue vaccine candidate, V181. This randomized, double-blind, placebo-controlled study aims to assess the primary endpoints of safety and efficacy of a single dose of V181 in preventing symptomatic virologically confirmed dengue of any serotype.

This Phase 3 trial marks a significant milestone in Merck's efforts to develop a vaccine for dengue, a mosquito-borne viral infection that affects millions of people worldwide. The initiation of this trial underscores Merck's commitment to advancing public health through innovative medical solutions.